Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Melinta stock doubles on FDA approval of a supplemental new drug application for BAXDELA to treat pneumonia

Proactive Investors Wednesday, 19 June 2019
Melinta Therapeutics Inc (NASDAQ:MLNT) stock rocketed Wednesday after it revealed the US Food and Drug Administration has accepted a supplemental New Drug Application (sNDA) for BAXDELA (delafloxacin) for priority review. The sNDA filing seeks to expand the current indication for BAXDELA to include adult patients with community-acquired bacterial pneumonia (CABP), which refers to pneumonia contracted by a person with little contact with the health care system. CAPB is the most common type of pneumonia, and a leading cause of illness and death.  Shares in the New Haven, Connecticut, pharma company more than doubled to $4.43.  READ: Melinta Therapeutics stock climbs after it highlights positive 4Q sales momentum The FDA granted priority review status to BAXDELA based on the previous Qualified Infectious Disease Product designation the drug enjoys, which offers incentives to drug makers to develop antibacterial and antifungal treatments for life threatening infections. Through this process, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date (proposed review deadline) of October 24, 2019. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date, or proposed review deadline date of October 24. "Due to the rise of antibiotic resistance and an aging population, community-acquired bacterial pneumonia, remains a challenge for healthcare professionals and has led to a need for new treatment options,” said Sue Cammarata, chief medical officer at Melinta Therapeutics. Cammarata said BAXDELA’s potency against the most common bacterial pathogens seen in CABP show it could play a “significant role” in the treatment of this illness, if approved. “We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible,” said Cammarata. The sNDA application is based on positive results from a Phase III, randomized, double-blind, study that compared the potency and safety of BAXDELA to moxifloxacin for the treatment of CABP. The study results showed that BAXDELA had comparable efficacy to moxifloxacin for early clinical response. Additionally, BAXDELA was generally safe and well-tolerated. The company said results from this study will be submitted for presentation at an upcoming medical conference. BAXDELA (delafloxacin) tablets and intravenous injection were approved by the FDA in 2017 for treating acute bacterial skin and skin structure infections. Contact Uttara Choudhury at [email protected] Follow her on Twitter: @UttaraProactive 
0
shares
ShareTweetSavePostSend
 
Credit: WMUR - Published < > Embed
News video: New program tested in NH to help prisoners with addiction

New program tested in NH to help prisoners with addiction 02:03

New Hampshire inmates are getting access to new drug treatment options that are aimed at saving their lives.

Recent related videos from verified sources

Mexican drug lord 'El Chapo' Guzman sentenced to life in prison [Video]Mexican drug lord 'El Chapo' Guzman sentenced to life in prison

The notorious drug cartel boss was found guilty on multiple conspiracy counts in an epic drug-trafficking case.

Credit: Al Jazeera STUDIO     Duration: 02:24Published

'El Chapo' to Serve Life in Prison [Video]'El Chapo' to Serve Life in Prison

'El Chapo' to Serve Life in Prison At a sentencing in a NYC district court, the Mexican drug lord was given an additional 30 years in prison. According to CNBC, "El Chapo," real name Joaquin Guzman..

Credit: Wibbitz Studio     Duration: 01:09Published

Joaquin Guzman aka 'El Chapo' Sentenced To Life Plus 30 Years [Video]Joaquin Guzman aka 'El Chapo' Sentenced To Life Plus 30 Years

The man who twice escaped from Mexican prisons, will now spend the rest of his life behind bars at a Supermax facility in the United States - but first Joaquín Guzmán had something to say. CBS2's..

Credit: CBS 2 New York     Duration: 02:29Published

'El Chapo' Set For Sentencing [Video]'El Chapo' Set For Sentencing

Mexican drug lord Joaquin “El Chapo” Guzman is set to be sentenced today in Downtown Brooklyn. CBS2's Jenna DeAngelis has the details.

Credit: CBS 2 New York     Duration: 01:37Published


Recent related news from verified sources

Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets

Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
DUBLIN--(BUSINESS WIRE)--Horizon announced that the U.S. FDA has accepted its New Drug Application for PROCYSBI® Delayed-Release Oral Granules in Packets.
Business Wire Also reported by •GlobeNewswire

Agile Therapeutics names industry veteran Dennis P. Reilly as CFO

Agile Therapeutics Inc (NASDAQ:AGRX) has announced the appointment of Dennis P. Reilly as its chief financial officer. Reilly, a veteran of the diagnostic and...
Proactive Investors Also reported by •GlobeNewswire

FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications

FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug...
Business Wire

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder

JERUSALEM & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug...
Business Wire

You Might Like


Other recent news in Business

MasterChef judge George Calombaris fined for underpaying staff $8.1 MILLIONeBay invests $150 million in PAYTM MALL
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.